SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

06 Nov 2023 Evaluate
The revenue slipped marginally during the September 2023 quarter. A decline of about Rs. 10106.67 millions was observed as compared to Rs. 10483.09 millions during the corresponding quarter last year.Profit saw a slight increase of 7.47%to Rs. 2575.27  millions from Rs. 2396.30 millions.Operating profit surged to 3882.13 millions from the corresponding previous quarter of 3608.59 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 10106.67 10483.09 -3.59 18947.37 19052.07 -0.55 36165.28 44007.08 -17.82
Other Income 411.14 656.24 -37.35 763.21 1400.16 -45.49 2404.64 2239.40 7.38
PBIDT 3882.13 3608.59 7.58 6827.82 7054.54 -3.21 12590.13 17345.79 -27.42
Interest 9.14 17.17 -46.77 25.10 26.17 -4.09 74.14 52.40 41.49
PBDT 3872.99 3591.42 7.84 6802.72 7028.37 -3.21 11951.38 17293.39 -30.89
Depreciation 402.36 366.72 9.72 792.18 715.83 10.67 1467.36 1102.96 33.04
PBT 3470.63 3224.70 7.63 6010.54 6312.54 -4.78 10484.02 16190.43 -35.25
TAX 895.36 828.40 8.08 1559.45 1621.70 -3.84 2725.76 4068.88 -33.01
Deferred Tax 29.53 21.89 34.90 104.82 60.79 72.43 -27.99 140.08 -119.98
PAT 2575.27 2396.30 7.47 4451.09 4690.84 -5.11 7758.26 12121.55 -36.00
Equity 164.70 164.69 0.01 164.70 164.69 0.01 164.70 164.30 0.24
PBIDTM(%) 38.41 34.42 11.59 36.04 37.03 -2.68 34.81 39.42 -11.68

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×